These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36045716)

  • 1. A novel
    Deng L; Tian P; Qiu Z; Wang K; Li Y
    Open Life Sci; 2022; 17(1):846-850. PubMed ID: 36045716
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel
    Yan L; Zheng J; Pan Q; Liang Y; Yu P; Chen Q
    Front Oncol; 2023; 13():1264820. PubMed ID: 37706178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report.
    Zhu X; He Y; Wang Y; Lei Y; Su X; Liu Y; Wu S; He Z
    Onco Targets Ther; 2021; 14():4915-4920. PubMed ID: 34611409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Intergenic Gene Between
    Du J; Wang B; Li M; Wang C; Ma T; Shan J
    Front Oncol; 2022; 12():898954. PubMed ID: 35847849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
    Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
    Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.
    Zhou H; Xu B; Xu J; Zhu G; Guo Y
    Front Oncol; 2021; 11():670907. PubMed ID: 34168990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L; Hou F; Liu Y; Li W; Zhang H
    J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
    Imanishi N; Yoneda K; Taira A; Ichiki Y; Sato N; Hisaoka M; Tanaka F
    Surg Case Rep; 2018 Mar; 4(1):19. PubMed ID: 29524063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
    Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
    Front Oncol; 2021; 11():782682. PubMed ID: 35070986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
    Gu R; Shi Z; Duan T; Song M
    Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Two novel
    Liao S; Sun H; Wu J; Lu H; Fang Y; Wang Y; Liao W
    Front Oncol; 2022; 12():916315. PubMed ID: 35941871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up.
    Mo Z; Cai C; Yao J; Zhao J; Zhang M; Liu H; Mu X
    Front Genet; 2023; 14():1289346. PubMed ID: 38155713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
    Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.
    Gu X; Wang W; Wu W; Zhang Y; Shao L; Santarpia M; Christopoulos P; Myall NJ; Shi Z; Lou G
    Transl Lung Cancer Res; 2022 May; 11(5):902-909. PubMed ID: 35693284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.